Role of presepsin for the evaluation of sepsis in the emergency department

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1395-1400

  Pizzolato, Elisa ^a   Ulla, Marco ^a   Galluzzo, Claudia ^a   Lucchiari, Manuela ^a   Manetta, Tilde ^a   Lupia, Enrico ^a   Mengozzi, Giulio ^a   Battista, Stefania ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Emergency Department; Presepsin; Sepsis

Indexed keywords

GLYCOPROTEIN; PRESEPSIN; UNCLASSIFIED DRUG; CD14 ANTIGEN; PEPTIDE FRAGMENT; PRESEPSIN PROTEIN, HUMAN;

CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; EMERGENCY WARD; HUMAN; NEONATOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; EMERGENCY HEALTH SERVICE; SENSITIVITY AND SPECIFICITY;

BACTERIA (MICROORGANISMS);

ANTIGENS, CD14; EMERGENCY SERVICE, HOSPITAL; HUMANS; NEONATOLOGY; PEPTIDE FRAGMENTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 84921341841     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0199     Document Type: Review

References (38)

1. Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-55.
2. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004;8:222-6.
3. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-50.
4. Balci C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7:85-90.
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup: surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
6. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-7.
7. Romualdo LG, Torrella PE, González MV, Sánchez RJ, Holgado AH, Freire AO, et al. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin Biochem 2014;47:505-8.
8. Hausfater P. Biomarkers and infection in the emergency unit. Med Mal Infect 2014;44:139-45.
9. Mussap M, Noto A, Cibecchini F, Fanos V. The importance of biomarkers in neonatology. Semin Fetal Neonatal Med 2013;18: 56-64.
10. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002;323:17-29.
11. Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections. Sci World J 2010;10:1941-6.
12. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11:234-8.
13. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomised controlled trial. Lancet 2010;375:463-74.
14. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin And Survival Study (PASS) Group. Procalcitonin- guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048-58.
15. Camussi G, Mariano F, Biancone L, De Martino A, Bussolati B, Montrucchio G, et al. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol 1995;155:316-24.
16. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17:764-9.
17. Chenevier-Gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens YE. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? Clin Chim Acta 2014;427:34-6.
18. Charles PE, Gibot S. Predicting outcome in patients with sepsis: new biomarkers for old expectations. Crit Care 2014;18:108.
19. Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department. Crit Care 2013;17:R244.
20. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013;17:R168.
21. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012;18:891-7.
22. Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011;412:2157-61.
23. Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 2011;49:937-9.
24. Novelli G, Morabito V, Ferretti G, Pugliese F, Ruberto F, Venuta F, et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. Transplant Proc 2013;45:2750-3.
25. Urbonas V, Eidukaite A, Tamuliene I. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. Cytokine 2013;62:34-7.
26. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 2014;20:30-4.
27. Ishikura H, Nishida T, Murai A, Nakamura Y, Irie Y, Tanaka J, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care 2014;18:R19.
28. Popov DA, Pliushch MG, Ovseenko ST, Abramian MV, Podshchekoldina OO, Iarustovskii MB. SCD14-ST (presepsin) level monitoring in cardiac surgical patients during perioperative period. Anesteziol Reanimatol 2013;3:30-5.
29. Vodnik T, Kaljevic G, Tadic T, Majkic-Singh N. Presepsin (sCD14- ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med 2013;51:2053-62.
30. Cakir Madenci O, Yakupoʇlu S, Benzonana N, Yücel N, Akbaba D, Orçun Kaptanaʇasi A. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns 2013;40:664-9.
31. Palmiere C, Mussap M, Bardy D, Cibecchini F, Mangin P. Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities. Int J Legal Med 2013;127:799-808.
32. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al; on behalf of the ALBIOS Study Investigators. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014;18:R6.
33. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011;24(Suppl 2):12-4.
34. Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012;25:51-3.
35. Otero RM, Nguyen HB, Huang DT, Gaieski DF, Goyal M, Gunnerson KJ, et al. Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest 2006;130:1579-95.
36. Nguyen HB, Smith D. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med 2007;25:564-71.
37. Lippi G, Schena F, Montagnana M, Salvagno GL, Guidi GC. Acute influence of aerobic physical exercise on procalcitonin. Eur J Clin Invest 2008;38:784-5.
38. Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, et al; Maurice Rapin Institute Biomarkers Group. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections. Ann Intensive Care 2013;3:22.